Phase 1 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing and able to sign a consent form agreeing to take part in the study.
- You must be 18 years old or older at the time you sign the consent form.
- You must be reasonably able to carry out daily activities, as measured by a standard health scoring system (a score above 60% on the Karnofsky scale — confirm with trial site if unsure what this means for you).
- You must have been diagnosed with squamous cell carcinoma (a specific type of cancer) of the head and neck that has come back or spread, confirmed by a lab test, affecting areas such as the mouth, throat, voice box, or the area around the throat.
Who may not be able to join:
- You may not be eligible if you have, or have had, serious heart problems such as heart failure, blocked heart arteries, uncontrolled high blood pressure, an irregular heartbeat, or a heart attack in the past 6 months.
- You may not be eligible if you have had a stroke or a mini-stroke (a brief stroke-like episode) within the past 12 months.
- You may not be eligible if you have ever had a severe allergic reaction to either of two specific medications called cyclophosphamide or fludarabine.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
Phone: +1 919-445-4208
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Toxicity: NCI-CTCAE; Toxicity: Cytokine Release Syndrome (CRS); Toxicity: Immune effector cell-associated neurotoxicity syndrome (ICANS); Dose Limiting Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.